The Biostatistics Core is a shared resource organized to meet the statistical needs of the USC Norris Comprehensive Cancer Center (NCCC) investigators. Statisticians in the Biostatistics Core collaborate with investigators in all the Cancer Center Programs - Molecular Genetics, Tumor Microenvironment, Epigenetics and Regulation, Developmental Therapeutics, Cancer Epidemiology, Cancer Control Research, Genitourinary Cancers, Gastrointestinal Cancers, Women's Cancers, and Leukemia and Lymphoma. The specific objectives of the Biostatistics Core are: 1. To provide statistical support to investigators at the NCCC in the design, planning, conduct, analysis, and reporting of cancer research studies 2. To ensure, in collaboration with members of the Clinical Investigations Support Office (CISO), the Cancer Research Informatics Core (CRIC), that clinical trials approved by the Clinical Investigations Committee (CIC) are properly executed and provide high quality clinical and translational research data, and ensure, in collaboration with the Translational Pathology Core (TPC) and CRIC, that disease-based databases and associated tumor banks, which serve as a resource for translational research, are supported and maintained 3. To adapt and incorporate, or develop, innovations in statistical and clinical trials methodology into the design and analysis of cancer research studies. Members of the Biostatistics Core participate in conceptualization and development of Cancer Center research projects, analyses for publications, development or adaptation of statistical methods, oversight and coordination activities, and other unanticipated needs of the Cancer Center. Core competencies include experimental design and data analysis, database design and utilization, and bioinformatics and analysis of high-throughput data. In the current application we are requesting partial funding for five Ph.D. statisticians, three M.S. level statisticians, and one Ph.D. level bioinformatician.
The use of modern statistical methods, analytic techniques, data processing and database design is an essential requirement of successful cancer clinical and translational research. The Biostatistics Core of the NCCC plays the central role in assuring that this requirement is fulfilled in research conducted by members of the Cancer Center.
|Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401|
|Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13|
|Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62|
|Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6|
|Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37|
|Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77|
|Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002|
|Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89|
|Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202|
|Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18|
Showing the most recent 10 out of 345 publications